Thoracic perfusion of recombinant human endostatin (Endostar) combined with chemotherapeutic agents versus chemotherapeutic agents alone for treating malignant pleural effusions: a systematic evaluation and meta-analysis.

Rong Biaoxue,Yang Shuanying,Liu Hua,Gao Wenlong,Cai Xiguang

doi:10.1186/s12885-016-2935-4

Abstract

BackgroundEndostar is a new endogenous angiogenic inhibitor with implicated anti-tumor activity. This study was to investigate whether thoracic perfusion of Endostar could be used to control malignant pleural effusions (MPE).MethodsWe searched the databases of MEDLINE, Web of Science, EMBASE, Goggle, Cochrance Library and CNKI to select the studies regarding the efficacy of Endostar to treat MPE. A total of 13 randomised controlled trials (RCTs) with 1066 patients were included.ResultsThe overall response rate (ORR) (P < 0.001; odds ratio = 3.58) and disease control rate (DCR) (P < 0.001; odds ratio = 2.97) of Endostar combined with chemotherapeutic agents were significantly higher than those of chemotherapeutic agents alone. In addition, Endostar combined treatment remarkably promoted quality of life (QOL) of patients (P < 0.001; odds ratio = 3.04) compared with that of chemotherapeutic agents alone. Moreover, Endostar combined treatment did not have an impact on the incidence of adverse reactions (AEs) (P < 0.05).ConclusionsThe efficacy of Endostar combined chemotherapeutic agents was superior to chemotherapeutic agents alone through thoracic perfusion in treating MPE, which indicated that Endostar could be an effective agent for controlling MPE.

Highlights

Endostar is a new endogenous angiogenic inhibitor with implicated anti-tumor activity
If we found useful information that was intimately associated with Endostar in the reference lists of those studies, we should further look for additional studies and identified them
Criteria that studies were included and excluded Inclusion criteria: (1) studies must be designed to compare Endostar plus chemotherapeutic agents to chemotherapeutic agents alone; (2) patients must be given drugs through thoracic perfusion; (3) patients must be diagnosed with malignant pleural effusions (MPE); (4) outcome measures must be reported; and (6) the total cases of patients must be greater than or equal to 50

Summary

Introduction

Endostar is a new endogenous angiogenic inhibitor with implicated anti-tumor activity. This study was to investigate whether thoracic perfusion of Endostar could be used to control malignant pleural effusions (MPE). In China, lung cancer has been becoming a major cause of death in malignant tumors due to increasingly air pollution and deterioration of the natural environment. In 2015 in China, There is dreadful fact that 733,000 lung cancer cases were diagnosed and 610,000 patients will die from this disease [1]. Most of lung cancer patients always are accompanied with the event of Biaoxue et al BMC Cancer (2016) 16:888 cases are often resistant to standard chemotherapy agent, or eventually become chemoresistant. The fact is many chemotherapeutic agents are not as effective as we expected in treating MPE via thoracic perfusion [4]. Because of strong antineoplastic activity and low toxicity, these products have been used as alternative treatments for the control of MPE [5]

Methods

Results

Conclusion